4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
Metrics to compare | 4BB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4BBPeersSector | |
---|---|---|---|---|
P/E Ratio | −16.6x | −2.9x | −0.7x | |
PEG Ratio | 0.31 | −0.01 | 0.00 | |
Price / Book | −31.3x | 4.6x | 2.6x | |
Price / LTM Sales | 273.9x | 23.0x | 3.2x | |
Upside (Analyst Target) | 41.2% | 56.4% | 43.9% | |
Fair Value Upside | Unlock | 3.1% | 6.5% | Unlock |